


Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

The Eventide Healthcare & Life Sciences Fund seeks to provide long-term capital appreciation by investing in securities of healthcare and life sciences companies. The fund invests in companies that we believe demonstrate values and practices that are ethical, sustainable, and provide a good investment opportunity. The fund also invests in securities with significant near-term appreciation potential. Under normal market conditions, the Fund will invest at least 80 percent of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.


TOP HOLDINGS*

Collegium Pharmaceutical Inc (4.55%) Abuse-detrerant treatments for chronic pain	DBV Technologies SA (2.59%) Patient-friendly therapies for food and pediatric allergy patients
Supernus Pharmaceuticals Inc (3.14%) Pioneering new medicines in neurology and psychiatry	WaVe Life Sciences Ltd (2.57%) Targeted genetic therapies for patients impacted by rare diseases
Seattle Genetics Inc (3.01%) Antibody-drug combinations to treat lymphoma and other cancers	Spark Therapeutics Inc (2.57%) Developing one-time gene therapies for genetic diseases
Five Prime Therapeutics Inc (2.99%) Screening human proteins to discover and develop novel drugs	GW Pharmaceuticals PLC (2.40%) Innovative therapeutics focused on epilepsy and CNS disorders
Loxo Oncology Inc (2.99%) Treating cancer at the genomic level with targeted chemical therapies	Xencor Inc (2.40%) Engineering antibody immune functions to make better drugs

Growth of \$10,000



Fund Returns



* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

† These charts compare the Eventide Healthcare & Life Sciences Fund to index fund performance over the previous periods shown, and since inception. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes. Since Inception returns pertain to Class N and are annualized and assume the inception date of 27 December 2012. Performance will differ for other fund classes, based upon fees and commissions. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

‡ Returns pertain to Class N.

** The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index from fund inception on 27 December, 2012. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

†† Aggregate total return, not annualized.

‡‡ Annualized since inception returns assume an inception date of 27 December 2012.

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

OVERVIEW

Fund	Nasdaq	Sales Charge*	12b-1 Fees	Total Expenses	Minimum Investment
Class A	ETAHX	Front-end: 5.75%	0.25%	1.57%	\$1,000 or \$100 with AIP
Class C	ETCHX	None	1.00%	2.32%	\$1,000 or \$100 with AIP
Class I	ETIHX	None	0.00%	1.32%	\$100,000
Class N	ETNHX	None	0.20%	1.52%	\$1,000 or \$100 with AIP


Inception Date: 12/27/2012
 Net assets: \$350 million
 Redemption Fee: 1.00% if held for less than 180 days.

MANAGERS




Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women's Hospital and Children's Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

Portfolio Composition† % of portfolio



Equity market capitalization: \$6.93B average, \$1.02B median

Industry Allocation‡ % of portfolio



Market Risk**

	Std. Dev.	Beta	Alpha	R-Squared
3 Year (Annualized)	31.02%	1.41	1.12%	24.06%
5 Year (Annualized)	-	-	-	-
Inception (Annualized)††	28.85%	1.41	6.54%	26.72%

* Other expenses that apply to a continued investment in the fund are described in the Fund's prospectus.

† Companies valued at greater than \$10 billion are Large Cap; those at less than \$1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

‡ Industry Allocation is subject to change at any time, and should not be considered investment advice.

** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.

Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETNHX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETNHX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETNHX over beta times the Index. The R-Squared (R2) of ETNHX versus the Index is a measure of how closely related the variance of ETNHX returns and the variance of the Index returns are.

StyleADVISOR calculates R2 by squaring the correlation of monthly returns between ETNHX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 January 2013 and not Fund's actual inception date of 27 December 2012, as only full month data is included in the market risk calculations.

Mutual Funds involve risk including the possible loss of principal.

Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to under perform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, thus subject to additional risks. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Healthcare & Life Sciences Fund can be found in the fund's prospectus, which can be obtained at www.eventidefunds.com or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is distributed by Northern Lights Distributors, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.